No headlines found.
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 12-May 2:54 AM ET)
Business Wire (Mon, 11-May 12:08 PM ET)
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
Barinthus Biotherapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol BRNS.
As of July 31, 2026, BRNS stock price was flat at $0.56 with 11,279 million shares trading.
BRNS has a beta of 1.23, meaning it tends to be more sensitive to market movements. BRNS has a correlation of 0.06 to the broad based SPY ETF.
BRNS has a market cap of $22.77 million. This is considered a Sub-Micro Cap stock.
BRNS has underperformed the market in the last year with a price return of -62.3% while the SPY ETF gained +19.4%. BRNS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.2% and +0.4%, respectively, while the SPY returned +4.2% and +0.5%, respectively.
BRNS support price is $.51 and resistance is $.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BRNS shares will trade within this expected range on the day.
